Adithya K. Yadalam, MD

@preetsingh6s In our cohort of 90 men with prostate cancer (mean age 67.5; SD 8.1), the prevalence of clonal hematopoiesis was 20%.

@akyadalam Okay so clonal hematopoiesis makes the problem worse.😯 How common is this in older men with prostate cancer?🤔

Presenting our work on the intersection of clonal hematopoiesis, androgen deprivation therapy, and longitudinal coronary plaque change in men with prostate cancer – with much more to come. #ACC2026

And as always, grateful for the continued mentorship of @CardioOnc_ATL and @sagarapatel.

Working with lead trialists @sagarapatel and @CardioOnc_ATL on the REVELUTION RCT has been such an incredibly enriching experience. Much more to come in the world of prostate cancer therapeutics and CVD.

Now in @JAMACardio – the REVELUTION RCT. In this RCT of men with localized prostate cancer, we show that randomization to GnRH-agonist ADT was significantly associated with an increase in 12-month coronary artery plaque compared to GnRH-antagonist ADT. jamanetwork.com/journals/jamac…

Among men with localized #ProstateCancer, treatment with GnRH agonist leuprolide resulted in greater 12-month coronary plaque progression vs GnRH antagonist relugolix, driven by increased noncalcified plaque volume. ja.ma/46UCYTo

@JochenReiser Love all things Ishiguro – would also strongly recommend The Remains of the Day. Same emotional restraint, but instead about duty: both its dignity and its cost.

Just finished Never Let Me Go. Subtle, heartbreaking, and impossible to shake. This book is a tender meditation on love, mortality, and human worth. It’s also the kind of book that lingers long after the last page….🥲🙃

@AGangavelli @AlexRazavi @EmoryCCRI @emory_heart

Very nice editorial of our recent publication in @JCardFail describing the association of lipoprotein(a) with CV outcomes in patients with HF – appreciate the authors’ efforts and commentary on further contextualizing our findings to a clinical context. onlinejcf.com/article/S1071-…

@StefanoByer @JACCJournals @ICOSociety @UIowaCVFellows Big congrats, Stefano! Looking forward to reading it.

🫀🧬 Just published in @JACCJournals: EP! Excited to share our state-of-the-art review exploring the complex, two-way link between atrial fibrillation and cancer - and why it’s time for precision cardio-oncology Personalized biomarkers, genomics, imaging & AI are reshaping AF care in cancer, underscoring need for prospective studies integrating these tools Grateful to have collaborated with incredible mentors and colleagues on this tour de force @datsunian @drpaari @Dr_Mike_Fradley @UGrewalMD 🔗sciencedirect.com/science/articl…

Excited to share the final version of our manuscript in @Circ_Gen detailing our novel, large-scale proteomics risk score, which significantly improved risk prediction for incident cardio-kidney-metabolic disease in over >23,000 UK Biobank participants. ahajournals.org/doi/10.1161/CI…

In all, we show that the ProtRS significantly: ⭐️ Predicted incident CKM-D outcomes independent of trad'l RFs ⭐️ Enhanced incident CKM-D outcome risk discrimination beyond trad'l RFs ⭐️ Improved incident 10-year CVD risk prediction beyond participants' PREVENT scores 🧵 [8/X]

Moreover, the addition of the ProtRS to participants' PREVENT scores significantly improved 10-year incident CVD risk discrimination (C-index, 0.757 [95% CI, 0.730–0.784]; ΔC-index, 0.049 [95% CI, 0.028–0.071] beyond the PREVENT score alone 🧵 [7/X]

Now published in @Circ_Gen: 🧍 In 23,815 UK Biobank participants free of cardio-kidney-metabolic disease (CKM-D) 🧬 A large-scale proteomics risk score ⭐️ Significantly improved risk prediction for incident CKM-D beyond trad'l risk factors (RFs) 🧵 [1/X] doi.org/10.1161/CIRCGE…

@MohammedAlo Moreover, CCTA can also visualize positive remodeling (outward expansion rather than luminal stenosis), a classic way that high-risk coronary plaque can accumulate without necessarily narrowing the vessel lumen.

@MohammedAlo Dr. Alo, I really enjoy learning from you, but I am curious about your comment re: CCTA/soft plaque/stenosis in the current era of CCTA. Total plaque volume (inclusive of vessel wall imaging) is often measured on CCTA, which reflects all plaque independent of luminal stenosis.

Unfortunately, CCTA does not detect soft plaque unless it is encroaching on the lumen. You have plenty of plaque. If the LDL-C is over 55, most people are building plaque.